^
    13d
    Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov)
    P2, N=16, Terminated, ImmuneSensor Therapeutics Inc. | N=51 --> 16 | Trial completion date: Feb 2026 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Nov 2024; Change in ImmuneSensor corporate strategy
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    1m
    A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, ImmuneSensor Therapeutics Inc. | Phase classification: P1/2 --> P1 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    IMSA101
    2ms
    Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, ImmuneSensor Therapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    2ms
    Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC (clinicaltrials.gov)
    P2, N=6, Terminated, ImmuneSensor Therapeutics Inc. | N=46 --> 6 | Trial completion date: Feb 2026 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Sep 2024; Slow enrollment.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    3ms
    SPARK: Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University of Texas Southwestern Medical Center
    New P2 trial • Combination therapy • Checkpoint inhibition • Metastases
    |
    Opdivo (nivolumab) • IMSA101
    8ms
    The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. (PubMed, Nat Commun)
    Consistent with this, the use of IL-18 receptor negative CART impair anti-tumor responses in mice receiving combination treatment. In summary, we find that IMSA101 enhances CART function which is facilitated through STING agonist-induced IL-18 secretion.
    Journal • CAR T-Cell Therapy
    |
    STING (stimulator of interferon response cGAMP interactor 1) • IL18 (Interleukin 18)
    |
    IL18 elevation
    |
    IMSA101
    1year
    A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (clinicaltrials.gov)
    P1/2, N=2, Active, not recruiting, ImmuneSensor Therapeutics Inc. | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    IMSA101
    1year
    Safety and Efficacy Study of IMSA101 in Refractory Malignancies (clinicaltrials.gov)
    P1/2, N=40, Completed, ImmuneSensor Therapeutics Inc. | Recruiting --> Completed | N=115 --> 40 | Trial completion date: Dec 2023 --> Sep 2023
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    HR negative
    |
    IMSA101
    over1year
    Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov)
    P2, N=51, Recruiting, ImmuneSensor Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    over1year
    Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC (clinicaltrials.gov)
    P2, N=46, Recruiting, ImmuneSensor Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    over1year
    Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, ImmuneSensor Therapeutics Inc.
    New P2 trial • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    over1year
    Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov)
    P2, N=51, Not yet recruiting, ImmuneSensor Therapeutics Inc.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
    over1year
    Safety and Efficacy Study of IMSA101 in Refractory Malignancies (clinicaltrials.gov)
    P1/2, N=115, Recruiting, ImmuneSensor Therapeutics Inc. | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Oct 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    HR negative
    |
    IMSA101